Completed PHASE2 INTERVENTIONAL NCT00002240

Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs

Evaluation of the Safety and Antiviral Efficacy of a Novel HIV-1 Protease Inhibitor, BMS-232632, Alone and in Combination With d4T and ddI as Compared to a Reference Combination Regimen

Sponsor: Bristol-Myers Squibb

Conditions HIV Infections

Interventions Atazanavir Didanosine Nelfinavir mesylate Stavudine

Updated 8 times since 2017 Last updated: Apr 28, 2011 Started: Mar 31, 1999 Primary completion: Dec 31, 2001 Completion: Dec 31, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00002240, this PHASE2 trial focuses on HIV Infections and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 8 times since 1999, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb

Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Atlanta, United States , Birmingham, United States , Chicago, United States , Cleveland, United States , Dallas, United States , Denver, United States , Galveston, United States , New York, United States , Ottawa, Canada and 4 more locations